Cube Dx hybcell technology



Support of several clinical decisions based on a range of markers from only 100µL plasma in around 20min.

»HOME...Integrated Sepsis Diagnostics
Aim and Scope

Cube Dx’ patient monitoring delivers speedy status reports on biomarkers which are associated with clinical decisions to be made during treatment of serious infection or inflammation.

The tests have been conceived for the periodic testing of patients in such a manner that the minimum use of samples is involved and a simple and rapid analysis is available. The aim is to deliver a “picture” of the inflammation status which is as complete as possible and which quickly indicates any deterioration in the condition of the patient. To achieve this, the hybserver software collects the measurement values and delivers a graphic display of how the situation evolves over time.

Workflow and Technology

Small quantities (100μL) of ETDA-plasma are adequate as sample.

Both the sample and the reaction mixture are fed into the hybcell with a pipette. The prepared hybcells are transferred to the hyborg – the fully automatic device.

The analysis is initiated by a click on the start button. The tests are based on the principle of competitive- or sandwich-immunoassays (dependent on marker). In accordance with the competitive principle, the biomarkers in the sample compete with the competitor antigens in the reaction mix in an effort to bind to the antibodies on the hybcell surface. The greater the amount of biomarker in the sample the smaller is the number of competitor antigens which bind to the antibodies. Since the competitor-antigens carry a fluorescent dyestuff the measured signal is reduced.

In the case of the sandwich-principle the biomarkers bind to antibodies on the surface of the hybcell. Secondary fluorescent-marked antibodies mark the trapped biomarkers. The more biomarker molecules are present in the sample the higher is the measured signal. 

The measured values are interpreted by the software and presented within the measurement range as quantitative results in a tabulated report.

Sample matrices

Small quantities (100μL) of blood plasma are adequate as sample and these are collected in customary receiving systems such as ETDA tubes.


In addition to established inflammation markers such as CRP, PCT and interleukins, not so common markers are provided as well: 

  • CRP - is an acute-phase protein-marker in cases of inflammation
  • PCT - is elevated during bacterial infections
  • IL6 - is an acute-phase protein-marker. Its concentration is increased in cases of infection, but auto immune diseases, AIDS, lymphoma and organ rejection as well
  • IL8 - is an acute-phase protein-marker. Its concentration is increased in cases of infection, but auto immune diseases, AIDS, lymphoma and organ rejection as well
  • Serumamyloid A (SAA) – is an acute-phase protein-marker in cases of bacterial- and viral infections and also when transplant rejection occurs
  • Tachykinin (Substance P) – is a neurotransmitter and a marker for a late phase of sepsis
  • Cystatin C – a protease inhibitor which indicates kidney failure
  • NGAL - plays a role during primary infection defence concerning kidneys. Elevated values can be found in early stages of kidney damage.
  • Optional: suPar - is a protein marker activated by the inflammatory and immune system. Its levels are increased during elevated risk of SIRS, cancer and other diseases



Click for Available Literature